Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

The purpose of the trial is to evaluate the safety and efficacy of MarzAA for on-demand treatment and control of bleeding episodes in hemophilia A or B patients with inhibitors compared with their standard of care (SOC).

  • 0 views
  • 20 Jun, 2021
  • 43 locations
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

The purpose of the trial is to evaluate the PK, bioavailability, PD, efficacy and safety of MarzAA for on demand treatment and control of bleeding episodes in adult subjects with inherited bleeding disorders.

  • 0 views
  • 28 Jun, 2021
  • 20 locations
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

> Rivaroxaban, a direct coagulation factor a inhibitor, blocks the formation of the clot. ROCKET-AF study has shown that the efficacy of rivaroxaban is not inferior to that of warfarin in AF patients on stroke

heart failure
stroke
diabetes
warfarin
coagulation factor
  • 13 views
  • 11 Feb, 2021
  • 1 location
Study of Recombinant Human Coagulation Factor VIIa for Injection (F a) in Patients With Hemophilia.

Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of recombinant human coagulation factor VIIa for injection (Fa) in patients with hemophilia.

  • 0 views
  • 04 Mar, 2021
  • 1 location
The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients

The pivotal clinical data support prolonged dosing intervals of up to 14 days for routine prophylaxis in hemophilia B patients. The majority of adult and pediatric patients using Idelvion for routine prophylaxis had a median annualized spontaneous bleeding rate (AsBR) of 0.00. The majority (99%) of bleeding episodes were managed …

christmas disease
factor ix
coagulation factor
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study to Evaluate the Pharmacokinetics Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

The primary objectives of the study are to evaluate the PharmacokineticsSafety and tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in

  • 0 views
  • 21 Jul, 2021
  • 4 locations
Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)

Prospective assessment of vitamin K dependent coagulation factor levels after temporary warfarin reversal in participants with left ventricular assist devices (LAVD).

  • 0 views
  • 14 May, 2021
  • 1 location
A Phase 3 Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein Efanesoctocog Alfa (BIVV001) in Patients With Severe Hemophilia A

Primary Objective: To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: To evaluate the efficacy of BIVV001 as a prophylaxis treatment. To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes To evaluate BIVV001 consumption for the prevention and treatment of …

coagulant
severe haemophilia a
treatment regimen
cryoprecipitate
von willebrand factor
  • 13 views
  • 27 Feb, 2021
  • 3 locations
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult

  • 0 views
  • 26 Apr, 2021
  • 16 locations
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be

coagulation factor
severe haemophilia a
antihemophilic factor
  • 0 views
  • 24 Jan, 2021
  • 1 location